Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary of company secretaries in the medical consumables sector is 817,000 yuan [2] - Salary distribution among company secretaries is as follows: below 500,000 yuan (30%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (27%), and above 2,000,000 yuan (2%) [2] - The top three highest-paid company secretaries are: Gong Xingliang from Nanwei Medical (2.2161 million yuan), Zhu Yu from Microelectrophysiology (1.6764 million yuan), and Lin Qing from Weigao Orthopedics (1.6142 million yuan) [2] Age and Education Distribution - The age distribution of company secretaries shows that those aged 40-50 constitute 45%, while those over 50 account for 14%, and those aged 30-40 make up 36% [1] - The educational background of company secretaries is as follows: 7% have an associate degree, 45% hold a bachelor's degree, 43% possess a master's degree, and 5% have a doctoral degree [1] Salary Changes - The largest salary decrease was observed for Bai Xue from Xishan Technology, with a year-on-year decline of 54.09% [2] - The largest salary increase was recorded for Chen Bin from Weili Medical, with a year-on-year increase of 191.72% [2]

Core Viewpoint - Yicheng Group (08365.HK) announced a proposal to update the existing general mandate for the board to issue and deal with new shares equivalent to 20% of the company's issued share capital as of the date of the special general meeting [1] Group 1 - The board's proposal requires approval from independent shareholders at a special general meeting through an ordinary resolution [1] - The new general mandate is in compliance with the revised GEM Listing Rules effective from January 1, 2023, specifically Chapter 23 [1] - The share scheme proposed by the board also requires shareholder approval at the special general meeting to take effect [1]

Core Viewpoint - The board of Yichen Group (08365.HK) proposes to update the existing general mandate to allow the issuance of new shares equivalent to 20% of the company's issued share capital as of the date of the special general meeting [1] Group 1 - The new general mandate requires approval from independent shareholders at a special general meeting through an ordinary resolution [1] - The board recommends adopting a share scheme to comply with the revised GEM Listing Rules effective from January 1, 2023 [1] - The share scheme will also require approval from shareholders at the special general meeting before it can be implemented [1]

证券代码：301122 证券简称：采纳股份 公告编号：2025-072 采纳科技股份有限公司 关于使用部分闲置募集资金和自有资金 进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）召开的第三届董事会第十二次 会议、第三届监事会第十一次会议、2025 年第一次临时股东大会，分别审议通过 了《关于使用部分闲置募集资金和自有资金进行现金管理的议案》，同意公司及 全资子公司在确保不影响募集资金投资项目和公司正常经营，并有效控制风险的 前提下，使用额度不超过人民币 20,000 万元（含本数）的闲置募集资金（含超 募资金）和额度不超过人民币 80,000 万元（含本数）的自有资金进行现金管理。 使用期限自股东大会审议通过之日起 12 个月内有效。在上述额度和期限内，资 金可循环滚动使用。 同时，在额度范围内授权公司管理层行使相关投资决策权并签署相关文件， 具体由公司财务部负责组织实施。 具体内容详见公司在巨潮资讯网 （www.cninfo.com.cn）披露的相关公告。 注：公司与上述受托方无关联关系。 二、 ...

Group 1 - The core viewpoint of the news is that Canan Co., Ltd. has seen a significant decline in its financial performance, with a notable drop in revenue and net profit in the latest quarterly report [1] - As of August 1, Canan's stock closed at 23.56 yuan, up 3.38%, with a rolling PE ratio of 80.61, marking a new low in 91 days, and a total market capitalization of 2.88 billion yuan [1] - The average PE ratio for the medical device industry is 53.65, with a median of 37.22, placing Canan at the 100th position in the industry ranking [1] Group 2 - Canan Co., Ltd. specializes in the research, production, and sales of injection and puncture devices and laboratory consumables, recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province [1] - The latest quarterly report for Q1 2025 shows that Canan achieved an operating revenue of 72.71 million yuan, a year-on-year decrease of 34.28%, and a net profit of 7.68 million yuan, down 69.34%, with a gross profit margin of 31.15% [1] - As of July 18, 2025, Canan had 7,532 shareholders, a decrease of 64 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

采纳股份主营业务为医疗器械的研发、生产和销售，产品涵盖医用耗材、医疗设备等领域。公司所属板 块包括医疗器械、创业板综等。 截至2025年7月31日收盘，采纳股份股价报22.79元，较前一交易日下跌0.70%，成交额0.69亿元，换手 率4.46%。盘中振幅4.05%，最高触及23.62元，最低下探22.69元。 消息面上，公司公告称2025年第三次临时股东会审议通过了《关于补选第三届董事会非独立董事的议 案》。 风险提示：市场有风险，投资需谨慎。 资金方面，7月31日主力资金净流出194.29万元，占流通市值的0.13%。 ...

Meeting Information - The company will hold its third extraordinary general meeting of shareholders on July 31, 2025, at 14:30 [1] - Network voting will be available on the same day from 9:15 to 15:00 [1][2] - Shareholders can choose between on-site voting or network voting, but not both [2] Voting Procedures - Shareholders must register to attend the meeting, either in person or through a proxy [3][4] - The registration deadline for mail, email, or fax is July 30, 2025, at 16:00 [4] - The company provides a network voting platform through the Shenzhen Stock Exchange [7][8] Agenda Items - The meeting will review proposals, including the election of a non-independent director for the third board of directors [2][6] - Detailed content of the proposals will be disclosed in prior announcements [2]

证券日报网讯 7月31日晚间，采纳股份发布公告称，公司2025年第三次临时股东会于2025年7月31日召 开，审议通过了《关于补选第三届董事会非独立董事的议案》。 （文章来源：证券日报） ...

德恒上海律师事务所 关于 采纳科技股份有限公司 2025 年第三次临时股东会之 见证意见 渡恆上海津師事務所 DEHENG SHANGHA! LAW OFFICE 上海市东大名路 501 号上海白玉兰广场办公楼 23 层 电话：021-5598 9888 传真：021-5598 9898 邮编：200080 德恒上海律师事务所 关于采纳科技股份有限公司 2025年第三次临时股东会之见证意见 德恒上海律师事务所 关于 采纳科技股份有限公司 2025年第三次临时股东会之 见证意见 德恒 02G20220260-00011 号 致:采纳科技股份有限公司 德恒上海律师事务所接受采纳科技股份有限公司(以下简称"公司")的委 托,指派本所见证律师列席公司于 2025年7月 31 日 14:30 在江苏省江阴市祝 塘镇环西路 23 号采纳医疗办公楼一楼会议室召开的 2025 年第三次临时股东会 (以下简称"本次股东会"）,就本次股东会进行见证并出具本见证意见。 本所见证律师依据本见证意见出具目前已经发生或存在的事实和《中华人民 共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称"《证券法》")、 ...

证券代码：301122 证券简称：采纳股份 公告编号：2025-071 采纳科技股份有限公司 关于使用部分闲置募集资金和自有资金 注：公司与上述受托方无关联关系。 二、投资风险及风险控制措施 （一）投资风险分析 1、公司拟购买的投资产品属短期低风险型产品，但金融市场受宏观经济影 响较大，该项投资会受到市场波动的影响； 1 / 7 序 号 受托方 产品名称 产品 类型 金额 (万元) 起息日 到期日 预计年 收益 资金 类型 1 上海浦东发 展银行股份 有限公司 利多多公司稳 利 25JG3316 期 结构性 存款 3,000 2025 年 8 月 1 日 2025 年 8 月 29 日 0.70%- 2.20% 自有 资金 一、本次使用部分闲置自有资金进行现金管理的基本情况 进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）召开的第三届董事会第十二次 会议、第三届监事会第十一次会议、2025 年第一次临时股东大会，分别审议通过 了《关于使用部分闲置募集资金和自有资金进行现金管理的议案》，同意公司及 ...